Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Vifor Pharma AG, Medical Devices Deals, 2011 to YTD 2017 10
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Relypsa Secures USD2.6 Million in Venture Funding 13
Relypsa Raises US$80 Million In Series C Financing 14
Relypsa Secures USD62.4 Million in Venture Funding 16
Partnerships 17
Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 17
Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 18
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 19
Probi Enters Into Co-Marketing Agreement With Vifor Pharma 20
Licensing Agreements 21
Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 21
Vifor Pharma Expands Licensing Agreement with ChemoCentryx 22
Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 23
Vifor Pharma Expands Licensing Agreement with Roche 24
Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 25
Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 26
Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 27
Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 29
Hikma Pharma Enters Into Licensing Agreement With Vifor Pharma For Ferinject 30
Equity Offering 31
Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 31
Relypsa Raises USD172 Million in Public Offering of Shares 32
Relypsa Completes Public Offering Of Shares For US$101.2 Million 34
Relypsa Completes IPO For US$86.7 Million 36
Acquisition 38
Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 38
Relypsa May Sell Itself 40
Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach 41
Vifor Pharma AG – Key Competitors 42
Vifor Pharma AG – Key Employees 43
Vifor Pharma AG – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 46
Financial Announcements 46
Aug 08, 2017: Vifor Pharma Reports Strong H1 2017 Results And Raises Guidance 46
Corporate Communications 47
Oct 06, 2016: Galenica: New Management at Vifor Pharma and new Galenica Group CFO designated 47
May 10, 2016: Vifor Pharma appoints Colin Bond as Chief Financial Officer 48
Government and Public Interest 49
Feb 20, 2017: Vifor Pharma and ECCO Announces One-Year Research Grant for Iron Deficiency 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50
Vifor Pharma AG, Pharmaceuticals & Healthcare, Key Facts 2
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vifor Pharma AG, Deals By Therapy Area, 2011 to YTD 2017 9
Vifor Pharma AG, Medical Devices Deals, 2011 to YTD 2017 10
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Relypsa Secures USD2.6 Million in Venture Funding 13
Relypsa Raises US$80 Million In Series C Financing 14
Relypsa Secures USD62.4 Million in Venture Funding 16
Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 17
Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 18
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 19
Probi Enters Into Co-Marketing Agreement With Vifor Pharma 20
Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 21
Vifor Pharma Expands Licensing Agreement with ChemoCentryx 22
Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 23
Vifor Pharma Expands Licensing Agreement with Roche 24
Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 25
Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 26
Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 27
Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 29
Hikma Pharma Enters Into Licensing Agreement With Vifor Pharma For Ferinject 30
Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 31
Relypsa Raises USD172 Million in Public Offering of Shares 32
Relypsa Completes Public Offering Of Shares For US$101.2 Million 34
Relypsa Completes IPO For US$86.7 Million 36
Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 38
Relypsa May Sell Itself 40
Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach 41
Vifor Pharma AG, Key Competitors 42
Vifor Pharma AG, Key Employees 43
Vifor Pharma AG, Other Locations 44
Vifor Pharma AG, Subsidiaries 44